Endocrine Abstracts

Introduction: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have RAI-resistant disease, resulting in poor prognosis and high disease-related mortality. Current studies of individualized therapy with different MAPK inhibitors report restoring RAI-avidity in 50 – 70% of BRAF and RAS mutated and thyroid cancers with no detected driver mutation. Five recent case reports of rare NTRK and RET-PTC fusion-positive metast...